Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, is the founder of Emmaus Life Sciences, Inc., and the principal inventor of Endari, an L-glutamine therapy for treatment of sickle cell disease approved by FDA in July 2017. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium.
L-Glutamine Therapy Reduces Hospitalization for Sickle Cell Anemia and Sickle β°-Thalassemia Patients at Six Months – A Phase II Randomized Trial
Background: Increased oxidant stress plays an important role in the pathophysiology of sickle cell disease. Nicotinamide Adenine Dinucleotide (NAD) is an important anti-oxidant that protects hemoglobin as demonstrated in diseases such as methemoglobinemia. Early in-vitro studies have shown that L-glutamine, a precursor for NAD, reduced oxidant stre... Read More»
Yutaka Niihara, Henry Macan, James R. Eckman, Han Koh, Melanie L Cooper, Thomas R Ziegler, Rafael Razon, Kouichi R Tanaka, Charles W Stark and Cage S Johnson
Research Article: Clin Pharmacol Biopharm 2014, 3:116
Peer-reviewed Full Article
Peer-reviewed Article PDF